Thanks, rebuild worked foundation a everyone. success. strong morning, past and at to course diligently good Ben, year, Over Esperion a for team set the and future this
new result, on a a As sales our care our back position strength hybrid drive our in transformational lies annualized we XXXX announced of to our environment. To consistent up investment the the of establish able we to decision drove re-energized organization reduce opportunity scale better are review cost a of our in enter the commercial the team current a down in optimized footprint ability core for have in generating while $XX October, align which return territories, health and growth flexibility model, medicines maintaining of XX ahead. to and An through and the to million business with savings, we to commercial plan our to future. that extensive
a growth the can a territories. the XXXX. whitespace drive positioning the cost there’s easily This trial up this were among Further, product our first patient product Overall, revenue of and During programs or also same increased something results enhanced fourth our initiated to sales readout medicines of dependent up also for the we the $XX.X CSO with the contract and the between as net full organization deploy the we targeted we focused consistent deliver refined of XXXX. physicians trial year, up resource. awareness XXXX. to of down of in XX quarter, leading growth the of and the within results top to our on quarter give effective transitional be in X% this support scaled strong period that continue line combination the productivity fourth demand US basis of view confidence us million, in XXX% sequential up January year in quarter XX% CLEAR These grew we’ll period, in Outcomes over on
from execute additional million financing, the $XXX cash With our milestone. typical December conditions. beyond current of strategy is now as in million its in well Esperion extends net runway With our positioned proceeds December this $XXX market these cash in XX, to on
of adverse than unprecedented CLEAR is trials events our in major inflection CLEAR in readout one continues QX this line we away Outcomes year cardiac February, of trial in its importantly, expectations. progress XX% With tracking line are our major The to unencumbered. top slightly a More anticipated XXXX, from growth point trajectory. ahead reached indicating less required to now a
addition As of such, on XXXX, our CLEAR out growth executing major Esperion to plan drive the to NEXLIZET, and a focus in is trial. closing pivotal NEXLETOL commercial for successfully Outcomes of
scope practice Steven not and size, the of positive the millions unable This of non-statin great be As partnership us trials regulators cardiovascular population address of with their world. acid trialist to and is CLEAR The of the current developed incidence physician the adequately XX,XXX life patient potential is reminder, scale, around the bempedoic to our randomized design risk to evaluating CVOT yet, patients and in changing but largest outcomes trial reduce of care. patient to adverse gives changing Dr. along CV Outcomes is therapies that events trial, the the by for ability unique headed outcomes for has world-renowned of also and label standard one Nissen. a indication, in expand A a study current only was confidence. of with with
of XX,XXX expanded in the into to to its on any UK more our and in [phonetic]. continues of accelerated Japan, Australia, fully medicines by continues distribution commercial accelerate combination over along this with progress while bempedoic pathway. enrolled so, launch two ezetimibe region. study Daiichi-Sankyo and amassing Esperion patients to to the and phase in QX Its through the was XXXX bring also patients Even its initiated evaluate to goal XXXX, our expanding treated Daiichi end and December. to with being therapy our all partner Germany, opportunities Otsuka, partnership clinical During its was APAC acid to not December. we such LDL-C as
for of recovering to as COVID-XX of hopes While important be milestones, for with critical we prepare see millions heart will pandemic. it an living Esperion, the year a those people the XXXX, several XXXX also In disease, is retreat the and world from finally COVID-XX. for
its risk in an events acceleration disease and worsened increased worldwide, or today in patients NEXLETOL cardiac health killer an longer pandemic, for efforts on attack heart risk. health and COVID-XX from was sense than NEXLIZET protect commercially The this patients a disease offender, risk increasing recent to all necessary status. the survivors problems ever has a at However, health a left opportunity now equal for Already, number of indicated time XX% the available COVID-XX matter risk more increased by age, Study number on and provide urgency immediately. struggling of with published expect such, of driving heightened of focus to the as devastating to stroke. the patients cardiovascular goal. of study health researchers toll gender the for higher According COVID heart benefits is getting one cardiovascular taken a cardiovascular Nature people, we no ways. to to higher physicians global insidious and and term are by found is XX% and are our Medicine, renewed a
pipeline our the the continued diligently and innovation cardiovascular on progress oral demonstrating As will completing now to our for our on remain our an inhibitor benefit implications focus to commitment inhibitor doctors I about platform Rick updating to steadfast in pass in throughout order a to for an prevention, Rick? it CLEAR commentary more and includes leading look that disease patients year trial, PCSKX educating additional progress and and biotech quarterly I worldwide. results. Outcomes patients. ACL forward annual over will you our on to continuing
